Karyopharm Completes Patient Recruitment in Phase 3 SIENDO Study of Selinexor in Patients with Endometrial Cancer
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the...
United States Sharon Shacham Selective Inhibitor Of Nuclear Export Karyopharm Therapeutics Inc European Commission Drug Administration
Source: prnewswire.com